Open AccessIs Immunomodulatory Property of Hydroxychloroquine Beneficial for Severe COVID-19? A Hospital Based Retrospective Observational Study
Author(s) -
Mahesh Prasad Mohanta,
Debabrata Behera,
D. Das,
P. K. Mishra,
Siddhartha Satapathy,
Lavina Patnaik,
Saroj Badapanda,
Gayathri Prakash
Publication year - 2021
Publication title -
advances in bioscience and clinical medicine
Language(s) - English
Resource type - Journals
ISSN - 2203-1413
DOI - 10.7575/aiac.abcmed.v.9n.2p.27
Subject(s) - hydroxychloroquine , medicine , covid-19 , retrospective cohort study , observational study , disease , pandemic , intensive care medicine , infectious disease (medical specialty) , virology , outbreak
Since the beginning of the COVID-19 pandemic, Hydroxychloroquine is being prescribed by the doctors all over the world for the treatment as well as prevention of COVID-19 with varying results. As we know damage in severe COVID-19 disease occurs mainly via the immunological mechanism. There is an assumption that HCQ has immunomodulatory property and thus may have a beneficial role in severe COVID-19 disease. In this retrospective study, we describe our experience of using low dose of HCQ (200mg/day) in 27 hospitalized severe cases of COVID-19 disease. We found, though the use of HCQ resulted in improvements in chest X-rays, there was no significant reduction in the deaths in the cases where HCQ was used.